US Patent

US7288657 — Biphenyl compounds useful as muscarinic receptor antagonists

Composition of Matter · Assigned to Theravance Inc · Expires 2028-10-31 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of biphenyl compounds that act as muscarinic receptor antagonists.

USPTO Abstract

This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar<SUP>1</SUP>, R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>6</SUP>, R<SUP>7</SUP>, and R<SUP>8 </SUP>are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US7288657
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-10-31
Drug substance claim
Yes
Drug product claim
No
Assignee
Theravance Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.